SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-001106
Filing Date
2022-01-13
Accepted
2022-01-13 08:20:34
Documents
14
Period of Report
2022-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8k.htm   iXBRL 8-K 41134
2 ex99-1.htm EX-99.1 20067
3 ex99-1_001.jpg GRAPHIC 5891
  Complete submission text file 0001493152-22-001106.txt   246043

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20220113.xsd EX-101.SCH 3045
5 XBRL LABEL FILE prph-20220113_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE prph-20220113_pre.xml EX-101.PRE 22603
8 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3486
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 22527944
SIC: 2834 Pharmaceutical Preparations